Tackling the Tough Questions on TAAR1 in Schizophrenia: A Live Social Media Event
Вставка
- Опубліковано 15 вер 2024
- Join experts as they discuss on an accredited live social media event on recognizing new mechanisms of action & therapeutic targets in schizophrenia.
Christoph U Correll, MD & Jonathan M. Meyer, MD
This live social media event is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. and Otsuka America Pharmaceutical, Inc.
This activity is intended for psychiatrists, primary care physicians, critical care specialists, NPs, PAs, nurses, pharmacists, & other HCPs who provide care to patients with schizophrenia.
For Physicians:
Medscape, LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), & the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Disclaimer:
The educational activity presented here may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Viewers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
Christoph U Correll, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Acadia; Alkermes; Allergan; Angelini; Aristo; Boehringer Ingelheim; Cardio Diagnostics; Cerevel; CNX Therapeutics; Compass Pathways; Darnitsa; Gedeon Richter; Hikma; Holmusk; Intra-Cellular Therapies; Janssen/Johnson & Johnson; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Merck; Mindpax; Mitsubishi Tanabe Pharma; Mylan; Neurocrine; Newron; Noven; Otsuka; Pharmabrain; PPD Biotech; Recordati; Relmada; Reviva; Rovi; Seqirus; SK Life Science; Sunovion; Sun Pharma; Supernus; Takeda; Teva; Viatris
Speaker or member of speakers bureau for: AbbVie; Angelini; Aristo; Damitsa; Gedeon Richter; Hikma; Intra-Cellular Therapies; Janssen/J&J; Lundbeck; Mitsubishi Tanabe Pharma; Mylan; Otsuka; Recordati; Seqirus; Sunovion; Takeda; Viatris
Research funding from: Janssen; Takeda
Stock options from: Cardio Diagnostics; Mindpax; LB Pharma; Quantic
Jonathan M. Meyer, MD, has the following relevant financial relationships:
Consultant or advisor for: Alkermes; Cerevel; ITCI; Karuna; Neurocrine; Otsuka America, Inc.; Relmada; Sunovion; Teva
Speaker or member of speakers bureau for: Alkermes; ITCI; Janssen; Neurocrine; Noven; Sunovion; Teva
This is going to be a game change for Schizophrenia.
My own preference is for Newron's compound. Astonishing results in Phase II, currently recruiting for Phase III.
It wont come out it failed
This is a shame about ulotaront. Can they try again? They were saying the pandemic may have affected the results. We need more medications for schizophrenia.
Hello
Will this medication be out by 2024 in the usa?
Thank you.
It wont come out it failed
Expect Newron to launch in 2025 in the US.
The latest clinical trials were astounding!
noooooooooooooooooooooooooooooooooo it failed ulorent doesnt come on the market
I know I’m upset too. It’s been a year since there was any news. Apparently they had another schizophrenia phase 3 trial.